Pasireotide
| CAS No. | 396091-73-9 | Cat. No. | BCP28075 |
| Name | Pasireotide | ||
| Synonyms | SOM 230; SOM-230; SOM230; | ||
| Formula | C58H66N10O9 | M. Wt | 1047.23 |
| Description | Pasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. | ||
| Pathways | GPCR/G Protein | ||
| Targets | Somatostatin Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.